Rapport Therapeutics, Inc. (RAPP) company profile
Close on Nov 13, 2026Market cap $1.25BP/E –Yield –
About Rapport Therapeutics
Pharmaceutical Preparations, SIC 2834
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops small molecule precision medicines for patients with neurological and psychiatric disorders. The company utilizes a receptor-associated protein platform to target specific neuronal receptor assemblies. Its lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator in development for drug-resistant focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. In addition, the firm advances discovery-stage nicotinic acetylcholine receptor programs, including RAP-641 for chronic pain and migraine, alongside therapies for hearing and vestibular disorders. Its patient population comprises individuals affected by serious central nervous system and sensory conditions.
The company maintains its corporate headquarters in Boston, Massachusetts, and holds laboratory and office facilities in San Diego, California. Its operational presence and research efforts are located within the United States. As a development-stage entity, it operates in the biopharmaceutical sector without commercialized products.
Summary of the business section of Rapport Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Rapport Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 99 High Street, Suite 2100 02110
- Phone
- (857) 321-8020
- Website
- rapportrx.com
- Employees
- 84, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- RAPP
- Exchange
- Nasdaq
- IPO date
- Jun 7, 2024
- Shares outstanding
- 48M, Aug 3, 2026
- Public float
- $275.84M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2012593
- CUSIP
- 75383L102
- ISIN
- US75383L1026
- FIGI
- BBG01FRNQ4P1
- Share class FIGI
- BBG01FRNQ4V4
- EIN
- 88-0724208
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Abraham Ceesay | Chief Executive Officer, Director | 552,493 |
| Troy A. Ignelzi | Chief Financial Officer | 15,500 |
| Cheryl Gault | Chief Operating Officer | 139,914 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 212,063 |
| David Bredt | Chief Scientific Officer | 393,075 |
| Jeffrey Sevigny | Chief Medical Officer | – |
| Trv Gp V, Llc | Director | – |
| Third Rock Ventures VI, L.P. | Director | 7,401,933 |
| Third Rock Ventures GP VI, L.P. | Director | – |
| Trv Gp Vi, Llc | Director | – |
| Third Rock Ventures V, L.P. | Director | 8,678,314 |
| Third Rock Ventures GP V, LP | Director | – |
| James Healy | Director | 2,873,888 |
| Ramiro Sanchez | Director | 3,600 |
| Paul M. Silva | Director | 3,680 |
| Steven M. Paul | Director | 555,022 |
| Wendy B. Young | Director | 13,289 |
| John Maraganore | Director | 9,411 |
| Reid M. Huber | Director | 20,400 |
| Robert J. Perez | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Abraham Ceesay Chief Executive Officer | $652.93K | $5.16M | $431.06K | $24.77K | $6.27M | -36% |
| Troy Ignelzi Chief Financial Officer | $519.85K | $1.71M | $249.60K | $25.92K | $2.51M | +2% |
| Jeffrey Sevigny Chief Medical Officer | $561.09K | $2.10M | $283.78K | $77.85K | $3.02M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jun 7, 2024
- Offer price
- $17.00
- Securities offered
- 8,000,000
- Gross proceeds
- $136.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Dec 4, 2024
“The initial public offering price per share is $17.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 84 full-time employees, and approximately 33 of our employees have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 7, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 4, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?